TMCnet News

Incruse 2016-2017 U.S. Promotional Report - Research and Markets

[December 15, 2017]

Incruse 2016-2017 U.S. Promotional Report - Research and Markets

The "Incruse 2016 U.S Promotional Report" report has been added to Research and Markets' offering.

The 5 Key Questions Addressed by this Report:

How many physicians were reached by Incruse through personal promotion in 2016 and how does this compare to its peer set in the Chronic Obstructive Pulmonary Disease markets?
What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
How does GSK's depth of coverage vary within key specialties (e.g., Family Medicine, Internal Medicine, and Pulmonology) and how does this compare to its peers and the overall set of rep-acessible physicians?
How often are physicians receiving paid meals for Incruse throughout the year (e.g., monthly, quarterly, annually)?
Who were the most detailed prescribers and top paid speakers for Incruse in 2016?

Data Sources and Methodology:

We leverage company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available - covering payments to more than 900,000 U.S. healthcare professionals.
Over 45,800 paid interactions across 19,000 physicians made on behalf of Incruse were carefully examined to support our analysis. In addition, interaction data from 9 peer products (e.g. Advair, Anoro, Breo, Brovana, Daliresp, Perforomist, Spiriva, Stiolto, and Symbicort) was leveraged to provide benchmarking and market insights.